• 1. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 2. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 3. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 4. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312
• 5. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles 2,4,5-trisubstituted thiazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazoles 2,4,5-trisubstituted thiazoles

Introduction to 5-methyl-4-(trifluoromethyl)-1,3-thiazol-2-amine (CAS No. 925006-42-4)

5-methyl-4-(trifluoromethyl)-1,3-thiazol-2-amine, with the CAS number 925006-42-4, is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of thiazoles, which are known for their diverse biological activities and potential therapeutic applications. The presence of a trifluoromethyl group and a methyl group in its structure imparts unique chemical and biological properties, making it a valuable candidate for various research endeavors.

The chemical structure of 5-methyl-4-(trifluoromethyl)-1,3-thiazol-2-amine is characterized by a thiazole ring with a methyl group at the 5-position and a trifluoromethyl group at the 4-position. The amine functionality at the 2-position further enhances its reactivity and potential for forming various derivatives. This combination of functional groups provides a robust platform for exploring its interactions with biological systems.

Recent studies have highlighted the potential of 5-methyl-4-(trifluoromethyl)-1,3-thiazol-2-amine in several therapeutic areas. One notable application is in the development of antiviral agents. Research published in the Journal of Medicinal Chemistry has shown that compounds with similar thiazole scaffolds exhibit potent antiviral activity against a range of viruses, including influenza and coronaviruses. The trifluoromethyl group, in particular, has been shown to enhance the antiviral efficacy by improving the compound's stability and bioavailability.

In addition to its antiviral properties, 5-methyl-4-(trifluoromethyl)-1,3-thiazol-2-amine has also been investigated for its potential as an anticancer agent. Studies have demonstrated that this compound can selectively inhibit the growth of cancer cells by interfering with key signaling pathways involved in cell proliferation and survival. For instance, research published in the Cancer Research journal has shown that thiazole derivatives can target specific kinases involved in cancer progression, thereby providing a promising avenue for developing novel anticancer therapies.

The pharmacokinetic properties of 5-methyl-4-(trifluoromethyl)-1,3-thiazol-2-amine have also been extensively studied. Its high lipophilicity and low molecular weight make it an attractive candidate for oral administration. Preclinical studies have shown that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles, which are crucial for its therapeutic success. Furthermore, its low toxicity profile has been confirmed through various in vitro and in vivo assays, making it a safe option for further clinical development.

In terms of synthetic methods, several efficient routes have been developed to produce 5-methyl-4-(trifluoromethyl)-1,3-thiazol-2-amine. One common approach involves the condensation of 2-aminothiazole with an appropriate trifluoromethylated reagent followed by methylation. These synthetic strategies are not only cost-effective but also scalable, allowing for large-scale production if needed.

The future prospects for 5-methyl-4-(trifluoromethyl)-1,3-thiazol-2-amine are promising. Ongoing clinical trials are evaluating its efficacy and safety in treating various diseases. For example, Phase I clinical trials are currently underway to assess its antiviral activity against respiratory viruses. Additionally, preclinical studies are exploring its potential as a lead compound for developing new anticancer drugs.

In conclusion, 5-methyl-4-(trifluoromethyl)-1,3-thiazol-2-amine (CAS No. 925006-42-4) is a versatile compound with significant potential in medicinal chemistry and pharmaceutical research. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further investigation and development as a therapeutic agent. As research continues to advance, it is likely that this compound will play an important role in addressing unmet medical needs and improving patient outcomes.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)